

Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease.

Submission date 29/11/2004	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 30/11/2004	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 03/08/2007	Condition category Respiratory	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Peter Black

Contact details

Department of Medicine
University of Auckland
Private Bag 92019
Auckland
New Zealand
1001
+64 93737599 ext 89797
pn.black@auckland.ac.nz

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information**Scientific Title****Study objectives**

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet**Health condition(s) or problem(s) studied**

Chronic obstructive pulmonary disease

Interventions

N-acetylcysteine 600 mg twice daily or matching placebo.

All participants received standard care including oxygen, nebulised salbutamol, oral prednisone and antibiotics (if indicated).

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/06/2001

Completion date

01/10/2001

Eligibility

Key inclusion criteria

Patients admitted to hospital with an acute exacerbation of chronic obstructive pulmonary disease.

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

50

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/06/2001

Date of final enrolment

01/10/2001

Locations

Countries of recruitment

New Zealand

Study participating centre

Department of Medicine

Auckland

New Zealand

1001

Sponsor information

Organisation

Health Research Council of New Zealand

Sponsor details

PO Box 5541

Wellesley St

Auckland

New Zealand

1001

+64 93035200

info@hrc.govt.nz

Sponsor type

Government

Website

<http://www.hrc.govt.nz/>

ROR

<https://ror.org/00zbf3d93>

Funder(s)

Funder type

Government

Funder Name

Health Research Council of New Zealand (ref: HRC 01/206)

Alternative Name(s)

HRCNewZealand, HRC New Zealand, HRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

New Zealand

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	06/12/2004		Yes	No